NCT05121376 - A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Hereditary AngioedemaHAE

Interventions

GENETIC

Dose 1 of BMN 331

BMN 331 AAV Gene Therapy

GENETIC

Dose 2 of BMN 331

BMN 331 AAV Gene Therapy

GENETIC

Dose 3 of BMN 331

BMN 331 AAV Gene Therapy

GENETIC

Dose 4 of BMN 331

BMN 331 AAV Gene Therapy

GENETIC

Dose 5 of BMN 331

BMN 331 AAV Gene Therapy

GENETIC

Dose 6 of BMN 331

BMN 331 AAV Gene Therapy

GENETIC

Dose 7 of BMN 331

BMN 331 AAV Gene Therapy

Trial Locations (16)

2050

Royal Prince Alfred Hospital,, Camperdown

16802

The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center, Hershey

20815

Institute For Asthma & Allergy, Chevy Chase

27705

Duke Health, Durham

35209

AllerVie Clinical Research, Birmingham

39110

Mississippi Center for Advanced Medicine, Madison

43235

Optimed Research, LTD, Columbus

45267

University of Cincinnati (UC) Physicians Company, LLC, Cincinnati

63141

Washington University School of Medicine, St Louis

66211

Dr. Henry J. Kanarek Allergy, Asthma & Immunology, Overland Park

75231

AARA Research Center, Dallas

80907

Asthma & Allergy Associates P.C., Colorado Springs

85251

Medical Research of Arizona, Scottsdale

92122

University of California San Diego, San Diego

Unknown

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Universitario La Paz, Madrid